



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : **Glycoprotein And Apolipoprotein Biopolymer Markers Predictive of Alzheimers Disease**

SERIAL NUMBER : 09/993,344

FILING DATE : November 23, 2001

EXAMINER: : Chernyshev, Olga N.

GROUP ART UNIT : 1646

ATTORNEY DOCKET NO. : 2132.096

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on 6-5-03

Susan Idess

To: Mail Stop: Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUN 11 2003

DECLARATION UNDER 37 CFR § 1.132

TECH CENTER 1600/290

I, Ferris H. Lander, do hereby declare as follows:

1. I am a registered Patent Agent and am authorized to represent the inventor's and assignee in the application entitled "**Glycoprotein and Apolipoprotein Biopolymer Markers Predictive of Alzheimers Disease**", having U.S. Application Serial No. 09/993,344 filed November 23, 2001.

2. In order to provide data which would obviate any rejection/objection regarding completeness of the disclosure, I contacted Dr. George Jackowski, Chairman and Chief Science Officer


of Syn-x Pharma Inc., and asked to be provided with evidence of the absence of the 1873 dalton marker (amino acid residues 2-18 of SEQ ID NO:1) in normal human sera.

3. This declaration (including the attached figure) is provided in order to show a comparison of the indicated disease marker (the 1873 dalton marker; amino acid residues 2-18 of SEQ ID NO:1) to a normal/control group, so as to evidence that the marker is not present in normal human sera.

The attached figure, obtained from Dr. Jackowski, provides side-by-side profiles (obtained using techniques of mass spectrometry) of normal human sera versus sera from Alzheimers patients. This profile comparison clearly evidences the absence of the 1873 dalton marker (amino acid residues 2-18 of SEQ ID NO:1) in normal human sera.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

6/5/2003
Date


Ferris H. Lander
Ferris H. Lander
Reg. No. 43,377

\\\Ns2\staff data files\Ferris Lander's Files\FL\AMENDMNT.PAT\2132_096.132.wpd